3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
5
Glioma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Glioblastoma
3
Rhabdoid Tumor
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Lymphoma
2
Liposarcoma
2
Fallopian Tube Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Sarcoma, Synovial
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Osteitis Deformans
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Interventions
Letrozole
3
Fulvestrant
3
exemestane
2
Trastuzumab
2
Irinotecan
2
Docetaxel
2
Capecitabine
2
Anastrozole
2
ribociclib
1
palbociclib
1
irinotecan sucrosofate
1
abemaciclib
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Liposomes
1
Everolimus
1
Cyclophosphamide
1
Cell Separation
1
Aromatase Inhibitors
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Cancer Metastatic
×
ribociclib
×
Clear all
NCT03555877
2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2
Completed
56 enrolled